Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?
Endocrine-Related Cancer · 01.06.2025 · 32 (6)
DOI: 10.1530/erc-25-0025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, online erschienen am 30.05.2025. Verfasst von Yael Kusne und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Myelodysplastic Syndromes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Peptide receptor radionuclide therapy (PRRT) with lutetium-177-Dotatate (177Lu-DOTATATE) has transformed neuroendocrine tumor (NET) treatment, improving progression-free survival, symptom control, and quality of life. However, long-term hematologic toxicities, including therapy-related myeloid neoplasms (tMN), are increasingly recognized. These rare but severe complications, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), appear multifactorial, influenced by prior cytotoxic therapies, radiation exposure, clonal hematopoiesis, and germline predispositions. This review synthesizes data on PRRT-related hematologic toxicities, including findings from pivotal studies and real-world evidence. We explore risk factors, underlying mechanisms, and the potential role of biomarkers, such as clonal hematopoiesis and germline mutations, in predicting toxicity. Emerging approaches, including alpha particle radioligand therapy and advanced dosimetry, are explored as strategies to optimize patient selection and minimize adverse outcomes. To maximize the benefits of PRRT while safeguarding patient safety, future efforts should focus on integrating predictive biomarkers, refining treatment sequencing, and developing personalized risk-stratified approaches to therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Thorvardur R Halfdanarson, Mohamad Bassam Sonbol
Zitieren
APA
Kusne, Y., Patnaik, M. M., Halfdanarson, T. R., & Sonbol, M. B. (2025). Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?. Endocrine-Related Cancer, 32(6). https://doi.org/10.1530/erc-25-0025
Vancouver
Kusne Y, Patnaik MM, Halfdanarson TR, Sonbol MB. Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?. Endocrine-Related Cancer. 2025;32(6). doi:10.1530/erc-25-0025
BibTeX
@article{Kusne2025,
author = {Kusne, Yael and Patnaik, Mrinal M and Halfdanarson, Thorvardur R and Sonbol, Mohamad Bassam},
title = {Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?},
journal = {Endocrine-Related Cancer},
year = {2025},
volume = {32},
number = {6},
doi = {10.1530/erc-25-0025}
}
EUVIMED